Overview

A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema

Status:
Not yet recruiting
Trial end date:
2024-03-28
Target enrollment:
Participant gender:
Summary
This Phase 4 study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander.
Phase:
Phase 4
Details
Lead Sponsor:
Genentech, Inc.